News

Twenty-five institutions collaborate with Cofactor to validate OncoPrism for use in head and neck cancer patients.

In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma

NEW YORK – After announcing a collaboration with Intermountain Health spinout Culmination Bio earlier this week, Cofactor Genomics is “moving aggressively” to advance its OncoPrism [...]

Culmination Bio, a new Intermountain Health Company, and Cofactor Genomics, a predictive diagnostic immunotherapy company, today announced a partnership to leverage samples and data from one of [...]

This collection highlights our most downloaded cancer papers published in 2022. Featuring authors from around the world, these papers showcase valuable research from an international community.

SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in [...]

Jarret Glasscock, PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time.  Precision [...]

Readout from the national PREDAPT multicenter clinical trial presented at AGBT Precision Health Conference Cofactor Genomics, a Predictive Immune Modeling company, today presented initial results [...]

Comprehensive immune profiling may lead to better prediction of immunotherapy response What must we do to improve outcomes for cancer patients? The answer is simple – gain a better understanding [...]

A familiar refrain for those who have traveled on London’s tube, “mind the gap” is a warning to take caution while crossing between the station platform and the train door. In oncology, patients [...]